Systemic sclerosis (also called scleroderma) is a multi-system autoimmune disease with several organ- and life-threatening manifestations. Progress in developing effective treatments for scleroderma has, in part, been hampered by a lack of reliable, feasible, and valid outcome measures. The OMERACT Scleroderma Vascular Disease Working Group has been working to draft a core set of domains relevant to the study of two related manifestations of disease: Raynaud’s phenomenon and digital ulcers. This SIG, the first for this group, will outline the significant progress made to date and seek input from the OMERACT community about next steps in the process.